MKI67 and pancreatic neuroendocrine tumor: In a retrospective analysis of everolimus, 15 patients with pancreatic NET (4 first‐line and 11 following chemotherapy), who had WD morphology and a Ki‐67 <55% (median Ki‐67 30%), had a median PFS of 6 months and OS of 28 months.